ZBHHealthcare · Medical DevicesThe 27 Wall Street analysts covering Zimmer Biomet Holdings, Inc. hold a median 12-month price target of $105 — -4.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 4 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Zimmer Biomet Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (97): The share count has been shrinking and the company is not leaning on new borrowing.
Quality (57): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ZBH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −4.7% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | Argus Research | Reiterates | Buy | $125 |
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | $100 |
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | $83 → $100 |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | $92 → $106 |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 6 Aug 2026 | Bernstein | Maintains | Market Perform | — |
| 6 Aug 2026 | Bernstein | Maintains | Market Perform | $91 → $93 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $101 → $110 |
| 6 Aug 2026 | Stifel | Maintains | Buy | — |
| 6 Aug 2026 | Stifel | Maintains | Buy | $105 → $110 |
| 28 July 2026 | UBS | Assumes | Buy | $89 → $115 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | $95 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $120 → $110 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 29 Apr 2026 | Barclays | Maintains | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZBH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Zimmer Biomet Holdings, Inc. returned +7.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 49% of US stocks
Cheaper than 54% of US stocks
Cheaper than 37% of US stocks
Higher than 40% of US stocks
Higher than 66% of US stocks
Higher than 83% of US stocks
Higher than 76% of US stocks
Higher than 68% of US stocks
Higher than 56% of US stocks
Higher than 70% of US stocks
Higher than 71% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zimmer Biomet Holdings, Inc. has a market value of $18.5B and an enterprise value of $25.7B.
Revenue in the twelve months to 30 June 2026: $8.5B. The latest quarter grew 4.8% year on year.
Net income over the same four quarters: $807.0M, a 9.5% net margin.
Free cash flow in the twelve months to 30 June 2026: $1.4B.
Zimmer Biomet Holdings, Inc. spent $750.8M on share buybacks and $188.4M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 23.6×; forward P/E: 10.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.99%, paying out 23% of earnings.
Zimmer Biomet Holdings, Inc. employs 17,000 people — $501K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zimmer Biomet Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Benzinga reports that Zimmer Biomet is trading at a 52-week high after better-than-expected third-quarter earnings. The headline says the company lifted its annual growth outlook despite a challenging knee market.
Why it matters — The report highlights stronger earnings and an improved annual growth outlook amid challenges in the knee market.
The provided excerpt identifies a Seeking Alpha transcript of Zimmer Biomet Holdings, Inc.’s Q3 2026 earnings call but contains no details about the call.
Why it matters — ZBH watchers can note the earnings-call transcript is available, but the excerpt provides no results or commentary to assess.
Zimmer Biomet beat third-quarter earnings and revenue estimates and raised its 2026 outlook. Strong Hips and S.E.T. sales offset weakness in Knees, while margins remained under pressure.
Why it matters — The results and higher outlook offer ZBH watchers an update on performance across product areas and the company’s 2026 expectations, alongside continued margin pressure.
Zacks says Zimmer’s Q3 headline figures for the quarter ended September 2026 offer a view of its performance. The item focuses on comparing key metrics with Wall Street estimates and year-ago actuals.
Why it matters — Those comparisons provide context for ZBH watchers assessing the company’s quarterly performance.
Benzinga reported that U.S. stocks rose on Wednesday, with the Dow Jones gaining around 1,100 points. Zimmer Biomet was included in the headline listing stocks moving higher.
Why it matters — The item places Zimmer Biomet among stocks moving higher during a broad U.S. market advance.
The 27 Wall Street analysts covering Zimmer Biomet Holdings, Inc. have a median 12-month price target of $105, with estimates ranging from $93 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Zimmer Biomet Holdings, Inc., 8 rate it a Buy, 19 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zimmer Biomet Holdings, Inc. 92 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Zimmer Biomet Holdings, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (97 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies -4.7% from the last close, and Ticker Nerd's factor model ranks Zimmer Biomet Holdings, Inc. 92 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zimmer Biomet Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $93 to $130 over the next 12 months.
Zimmer Biomet Holdings, Inc. returned +7.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare.
The most recent item we track (Benzinga, 4 Nov 2026): "Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market". Benzinga reports that Zimmer Biomet is trading at a 52-week high after better-than-expected third-quarter earnings. The headline says the company lifted its annual growth outlook despite a challenging knee market.
Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip systems, along with sports medicine, biologics, extremities, and trauma solutions. Its portfolio also includes craniomaxillofacial and thoracic products, office-based technologies, bone cement, surgical instruments, and integrated digital and robotic technologies used in orthopedic procedures. Zimmer Biomet serves healthcare professionals, hospitals, and surgical centers by providing products that support the treatment of bone, joint, and soft-tissue disorders. Headquartered in Warsaw, Indiana, Zimmer Biomet plays an important role in orthopedic care across major markets worldwide.
CEO Mr. Ivan Tornos · 17,000 employees · United States · https://www.zimmerbiomet.com
